Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:ABCNNYSE:EMCNYSE:FRXNASDAQ:ONC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCNVIVO CannabisC$1.32+5.6%C$1.32C$0.80▼C$4.06C$256.62MN/A1.51 million shs310,601 shsEMCEMC$28.18+0.1%$0.00$22.99▼$29.13N/AN/A13.90 million shs5,177 shsFRXForest Road Acquisition$10.30$9.72▼$18.20$450MN/A2.07 million shs40,482 shsONCBeOne Medicines$247.55-2.1%$245.25$141.31▼$287.88$27.12B0.3444,743 shs93,632 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCNVIVO Cannabis0.00%0.00%0.00%0.00%0.00%EMCEMC+0.10%-2.08%+0.19%+4.24%+3.31%FRXForest Road Acquisition0.00%0.00%0.00%0.00%0.00%ONCBeOne Medicines0.00%-8.59%+6.72%+0.32%+25,277,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCNVIVO CannabisN/AN/AN/AN/AN/AN/AN/AN/AEMCEMC0.5355 of 5 stars0.02.01.70.00.01.70.7FRXForest Road AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AONCBeOne Medicines2.4476 of 5 stars3.50.00.00.02.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCNVIVO Cannabis 0.00N/AN/AN/AEMCEMC 0.00N/AN/AN/AFRXForest Road Acquisition 0.00N/AN/AN/AONCBeOne Medicines 3.00Buy$319.0028.86% UpsideCurrent Analyst Ratings BreakdownLatest ONC, ABCN, EMC, and FRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.005/8/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$348.00 ➝ $350.004/28/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.004/24/2025ONCBeOne MedicinesTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$334.00 ➝ $334.004/21/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.004/16/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/10/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$348.00 ➝ $348.004/7/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$312.004/7/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy$312.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCNVIVO CannabisN/AN/AN/AN/AN/AN/AEMCEMCN/AN/AN/AN/AN/AN/AFRXForest Road AcquisitionN/AN/AN/AN/A$0.56 per shareN/AONCBeOne Medicines$3.81B7.12N/AN/A$34.10 per share7.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCNVIVO CannabisN/AN/A0.00∞N/AN/AN/AN/AN/AEMCEMCN/A$2.0513.75∞N/AN/AN/AN/AN/AFRXForest Road Acquisition-$7.92MN/A0.00N/AN/AN/AN/AN/AN/AONCBeOne Medicines-$644.79M-$3.72N/A348.66N/A-9.40%-7.55%-4.42%N/ALatest ONC, ABCN, EMC, and FRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCNVIVO CannabisN/AN/AN/AN/AN/AEMCEMC$0.461.63%N/A22.44%N/AFRXForest Road AcquisitionN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCNVIVO CannabisN/AN/AN/AEMCEMCN/AN/AN/AFRXForest Road AcquisitionN/A0.370.37ONCBeOne Medicines0.051.961.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCNVIVO CannabisN/AEMCEMC79.86%FRXForest Road AcquisitionN/AONCBeOne Medicines48.55%Insider OwnershipCompanyInsider OwnershipABCNVIVO CannabisN/AEMCEMC0.40%FRXForest Road AcquisitionN/AONCBeOne Medicines6.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCNVIVO CannabisN/A194.41 millionN/ANot OptionableEMCEMCN/AN/AN/ANot OptionableFRXForest Road AcquisitionN/A37.50 millionN/ANot OptionableONCBeOne Medicines11,000109.56 million102.31 millionN/AONC, ABCN, EMC, and FRX HeadlinesRecent News About These CompaniesBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee Sells 422 SharesJune 19 at 7:48 AM | insidertrades.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Sells $118,143.90 in StockJune 18 at 6:24 PM | marketbeat.comInsider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) COO Sells 630 Shares of StockJune 18 at 6:22 PM | marketbeat.comInsider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Sells 1,177 Shares of StockJune 18 at 5:58 PM | marketbeat.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO Sells $374,475.40 in StockJune 18 at 5:58 PM | marketbeat.comInsider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) COO Sells 1,543 Shares of StockJune 18 at 5:56 PM | marketbeat.comJohn Oyler Sells 3,680 Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) StockJune 18 at 5:56 PM | marketbeat.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee Sells 422 SharesJune 18 at 5:37 PM | marketbeat.comGlenmark Pharma: FDA concludes inspection at US facility, issues five observationsJune 18 at 6:55 AM | financialexpress.comBeigene (NASDAQ:ONC) Stock Price Down 5.4% - Should You Sell?June 17 at 2:05 PM | marketbeat.comBeigene (NASDAQ:ONC) Shares Gap Down - What's Next?June 16, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) Receives $319.00 Consensus Target Price from AnalystsJune 16, 2025 | americanbankingnews.comBeOne Medicines verlegt Sitz in die Schweiz und startet neues Kapitel der weltweiten KrebsforschungJune 14, 2025 | afp.comBeOne Medicines showcases breakthrough data at EHAJune 13, 2025 | thepharmaletter.comBeigene, Ltd. (NASDAQ:ONC) Insider Sells $34,620.24 in StockJune 13, 2025 | insidertrades.comBeigene, Ltd. (NASDAQ:ONC) Receives Consensus Rating of "Buy" from AnalystsJune 13, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) Insider Sells $34,620.24 in StockJune 12, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) Insider Sells $10,975,363.20 in StockJune 12, 2025 | marketbeat.comBeigene (NASDAQ:ONC) Shares Gap Up - Still a Buy?June 12, 2025 | marketbeat.comBeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025June 12, 2025 | businesswire.comBeigene (NASDAQ:ONC) Shares Down 0.1% Following Insider SellingJune 12, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsBy Leo Miller | May 27, 2025View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsTurbulence for Joby Shares: What's Behind the Recent Dip?By Jeffrey Neal Johnson | May 22, 2025View Turbulence for Joby Shares: What's Behind the Recent Dip?RKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernPalantir Soars on Government Deals as Valuation Debate LingersBy Chris Markoch | June 3, 2025View Palantir Soars on Government Deals as Valuation Debate LingersONC, ABCN, EMC, and FRX Company DescriptionsVIVO Cannabis CVE:ABCNC$1.32 +0.07 (+5.60%) As of 08/3/2018ABcann Global Corporation manufactures and distributes medical cannabis. The company is headquartered in Napanee, Canada.EMC NYSE:EMCEMC Corporation (EMC) develops, delivers and supports the information technology (IT) industry's range of information infrastructure and virtual infrastructure technologies, solutions and services. EMC manages the Company as part of a federation of businesses: EMC Information Infrastructure, VMware Virtual Infrastructure, Pivotal and Virtustream. EMC's Information Infrastructure business provides a foundation for organizations to store, manage, protect, analyze and secure information. EMC's VMware Virtual Infrastructure business is engaged in virtualization and cloud infrastructure solutions that enable businesses to help transform the way they build, deliver and consume IT resources in a manner that is based on their specific needs. EMC's Pivotal business unites strategic technology, people and programs from EMC and VMware and has a platform that consists of data, agile development practices and a cloud independent platform-as-a-service.Forest Road Acquisition NYSE:FRXForest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.BeOne Medicines NASDAQ:ONC$247.55 -5.23 (-2.07%) As of 12:46 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Dan Ives Just Unveiled His AI ETF—Does It Live Up to the Hype? Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
